used a mouse model showing that pre-existing STAT3 in myeloid cells that contribute to tumors such as MDSCs can considerably direct the TLR9 signaling process to the tumor angiogenesis and inhibition of antitumor immune responses (41). Here, TLR9 is linked to neoplasm.